AngioDynamics (NASDAQ:ANGO) Second Quarter 2023 Results

Key Financial Results

• Revenue: US$85.4m (up 9.1% from 2Q 2022).

• Net loss: US$8.49m (loss widened by 1.6% from 2Q 2022).

• US$0.21 loss per share (further deteriorated from US$0.21 loss in 2Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

AngioDynamics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 10% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on AngioDynamics' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here